Article

A Validated Mathematical Model of FGFR3-Mediated Tumor Growth Reveals Pathways to Harness the Benefits of Combination Targeted Therapy and Immunotherapy in Bladder Cancer

2024-01-30

Abstract excerpt

Bladder cancer is a common malignancy with over 80,000 estimated new cases and nearly 18,000 deaths per year in the United States alone. Therapeutic options for metastatic bladder cancer had not evolved much for nearly four decades, until recently, when five immune checkpoint inhibitors were approved by the FDA. Despite the activity of these drugs in some patients, the objective response rate for each is less than...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2e8199f4-0fb5-5a3d-abcc-72327d3ad51b
DOI: 10.22541/au.170664414.42348543/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Validated Mathematical Model of FGFR3-Mediated Tumor Growth Reveals Pathways to Harness the Benefits of Combination Targeted Therapy and Immunotherapy in Bladder CancerDOI 10.22541/au.170664414.42348543/v1Read

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.Semantic proximity Read

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read

Simulation Models for Bladder Cancer: A Scoping ReviewSemantic proximity Read

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read

Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.Semantic proximity Read

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read

Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting.Semantic proximity Read

Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.Semantic proximity Read

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.Semantic proximity Read

Enhancing Predictive Accuracy in Immunotherapy Models through Data Integration and Parameter IdentifiabilitySemantic proximity Read

Dual Targeting of FGFR3 and ERBB3 Enhances The Efficacy of FGFR Inhibitors in FGFR3 Fusion-Driven Bladder CancerSemantic proximity Read

Classical Mathematical Models for Prediction of Response to Chemotherapy and ImmunotherapySemantic proximity Read